Pfizer Inc. (NYSE:PFE), IBM team up in research to combat Parkinson’s disease

Share on FacebookTweet about this on TwitterShare on Google+Share on RedditShare on LinkedInPrint this pageEmail this to someone

Pfizer Inc. (NYSE:PFE) doesn’t dwell on disappointments. After ending its pursuit of Allergan PLC (NYSE:AGN) on a disappointing note, Pfizer is looking ahead. The company recently announced a partnership with the International Business Machines Corp. (NYSE:IBM) that would see it benefit from the latter’s cognitive computing technology in future clinical trials.

Pfizer Inc. (NYSE:PFE) and IBM have come together to jointly launch a research initiative focused on Parkinson’s disease. Their target is to understand more about the neurological condition so as to improve the kind of care that patients afflicted with the condition receive. The collaboration is also expected to help accelerate clinical trials for new medicines to combat Parkinson’s disease.

A house enriched with sensors

The joint research facility will be located in Yorktown Heights, NY, near IBM’s Watson Research Center. The facility will be designed in the form of a regular house, but will be equipped with multiple sensors to collect data on various elements of Parkinson’s disease. The idea of equipping the research house with sensors will be to facilitate real-time collection of data about how patients are responding to treatments and the progression of their conditions. Some of the data that will be fetched from Parkinson’s disease patients in the research house include motor function, cognition and daily activities such as eating and dressing.

Pfizer Inc. (NYSE:PFE) and IBM said they will include control subjects in the research house.

Leveraging IBM’s cognitive computing technology, the researchers at the joint Parkinson’s disease research center will be able to understand the unique link between the symptoms and timing or dosing of medicine. That should help in developing the right dose of a particular drug for the patients. That way, Pfizer can be able to speed up its clinical trials of Parkinson’s disease drug candidates.

Pfizer Inc. (NYSE:PFE) has a Parkinson’s disease targeted experimental drug called PF-06649751, which is expected to enter Phase 3 trial in 2019.

Other conditions

Although the initial focus is on Parkinson’s disease, Pfizer Inc. (NYSE:PFE) is hopping that it would in the future expand the program with IBM to include research into other devastating conditions such as Alzheimer’s and Huntington’s diseases.

Neha Gupta

Neha Gupta has been in the financial space for over six years now. Gupta earned her MBA degree from Symbiosis Centre of Distance Learning in 2009 and her passion for finance led her to pursue Chartered Financial Analyst (CFA) course. She has successfully completed Level II of her CFA. She is a veteran in article writing, which is depicted in her numerous pieces published on SeekingAlpha, Nextiphonenews, InsiderMonkey, MarketWatch, and Techinsider. Her crisp and eloquent writing finds its best place in Researchcows, where emphasis is given on developing rich content for various websites, products, business plans, trainings, and book writing.

You may also like...

More in IBM
IBM Cloud
International Business Machines Corp. (NYSE:IBM) To Help Develop Brain-Inspired Supercomputer For Nuclear Environment

International Business Machines Corp. (NYSE:IBM) and a federal facility known as Lawrence Livermore National Laboratory (LLNL) are getting together to...

Close